Rockwell Medical

RMTI · Nasdaq · United States

Share price · RMTI

$6.10-1.42 (-18.88%) 3M

close as of 2026-11-18 · 24h delayed · vol 30K (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RMTI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+17.1%
  2. 7 Oct 2026+7.5%

    Nothing announced by RMTI that day or the session before.

  3. 28 Aug 2026+5.4%

    Nothing announced by RMTI that day or the session before.

  4. 29 Jun 2026-9.2%
  5. 16 Jun 2026+6.3%
  6. 11 Jun 2026-7.5%
  7. 6 May 2026-5.8%

    Nothing announced by RMTI that day or the session before.

  8. 20 Jan 2026+31.3%
  9. 5 Jan 2026+15.1%
  10. 26 Dec 2025+6.2%

    Nothing announced by RMTI that day or the session before.

Share of unusual movement by asset

For each asset, the share of RMTI's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—32%
Sessions with no dated event—68%

No dated announcements about its assets since 2 Jul 2024.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Approved
Iron-replacement therapy delivered via dialysateSmall molecule
Chronic Kidney DiseaseIron Deficiency Anemia

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$19M$0.1M$11M+ $12M short-term inv.$2.3M-$1.5M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$18M<$0.1M$11M+ $14M short-term inv.$1.2M$2.1M operating cash flowreport ↗
2026-Q1$17M—$9.6M+ $14M short-term inv.$1.6M-$0.2M operating cash flowreport ↗
2025-Q3$16M$0$14M+ $10M short-term inv.$1.8M-$1.3M operating cash flowreport ↗
2025-Q2$16M$0$12M+ $5.9M short-term inv.$1.5M$1.8M operating cash flowreport ↗
2025-Q1$19M$0$11M+ $5.9M short-term inv.$1.5M-$3.5M operating cash flowreport ↗
2024-Q3$28M$0$12M+ $5.9M short-term inv.—$4.3M operating cash flowreport ↗
2024-Q2$26M$0$12M+ $0 short-term inv.—$1.4M operating cash flowreport ↗
2024-Q1$23M<$0.1M$6.6M+ $2.0M short-term inv.$1.7M-$2.4M operating cash flowreport ↗
2023-Q3$24M$0.5M$7.8M+ $4.0M short-term inv.$1.9M-$3.8M operating cash flowreport ↗
2023-Q2$18M$0.2M$9.0M+ $5.9M short-term inv.$3.3M-$1.7M operating cash flowreport ↗
2023-Q1$20M$0.3M$11M+ $5.9M short-term inv.$1.8M-$3.9M operating cash flowreport ↗
2022-Q3$19M$0.5M$13M+ $15M short-term inv.$4.2M-$1.1M operating cash flowreport ↗
2022-Q2$19M$0.9M$31M+ $0 short-term inv.$5.0M-$5.9M operating cash flowreport ↗
2022-Q1$16M$1.6M$9.9M+ $0 short-term inv.$7.2M-$9.8M operating cash flowreport ↗
2021-Q3$16M$1.2M$23M+ $9.8M short-term inv.$7.6M-$7.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$69M$0$11M+ $14M short-term inv.$1.3M-$0.7M operating cash flowreport ↗

Rockwell Medical reported FY2025 revenue of $69.26M, down 31.8% YoY from $101.49M, and R&D spend of $0M, down 100.0% YoY from $0.02M. Cash and cash equivalents were $10.71M, while cash and cash equivalents plus investments available-for-sale totaled $25.0M at year-end; the company recorded a net loss of $5.31M for the year.

Management said 2025 results were in line with annual guidance and that the company remained profitable on an Adjusted EBITDA basis for the second consecutive year. 2026 guidance projects Adjusted EBITDA of $1M to $2M with positive operating cash flow. During the year, Rockwell extended its purchase agreement with one of the largest U.S. dialysis providers through December 2026 with increased pricing, added 30 new western U.S. customers in the fourth quarter, signed a multi-year agreement with Innovative Renal Care, and added a 510(k)-approved single-use bicarbonate cartridge to its portfolio, along with several leadership appointments.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$101M<$0.1M$16M+ $5.9M short-term inv.$0.1M$4.2M operating cash flowreport ↗
2023-FY$84M$1.1M$9.0M+ $1.9M short-term inv.$2.1M-$9.4M operating cash flowreport ↗
2022-FY$73M—$10M+ $11M short-term inv.$4.7M-$17M operating cash flowreport ↗
2021-FY$62M—$13M+ $9.2M short-term inv.$8.2M-$34M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($12K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Strobeck Mark · director, President and CEOOpen-market sale1,000$8.42$8KForm 4
2026-07-01Strobeck Mark · director, President and CEOAward / grant30,000——Form 4
2026-07-01Neri Jesse · SVP and CFOAward / grant15,000——Form 4
2026-07-01TIMMINS MEGAN C. · EVP, CLO & SecretaryAward / grant15,000——Form 4
2026-07-01Hunter Heather · Chief Operating OfficerAward / grant15,000——Form 4
2026-07-01Chole Timothy · SVP and CCOAward / grant15,000——Form 4
2026-07-01COOPER JOHN G · directorAward / grant9,633——Form 4
2026-07-01Radie Robert S · directorAward / grant9,633——Form 4